Synthes reported total net sales as $907.2 million in worldwide net sales for the third quarter of the 2010 fiscal year, a 4.5 percent increase from last year's third quarter results, according to a company news release.
The increase is partially attributed to a 2.1 percent increase in the North American sales from the third quarter of 2009. There were strong sales in trauma, attributed to launching new product lines and the continued success of the Matrix facial plating system. The sales of spine products were weaker in the United States, reflecting external challenges and product launch delays.
European sales decreased from $198.6 million during the third quarter of 2009 to $196.5 million during the third quarter of 2010. While Synthes performed well in the trauma market with products such as the Variable Angle LCP and the MatrixMIDFACE, the company struggled with the launch of "Matrix Spine" and targeted competitive conversion initiatives.
Read the release on Synthes 3Q FY 2010 report.
Read other coverage on Synthes:
- Court Issued Mixed Ruling in Medtronic's Appeal of Synthes Patent Dispute
- Synthes Announces 9% Sales Growth in 2009
- Synthes Recalling its Synex II Central Body Spinal Implant
The increase is partially attributed to a 2.1 percent increase in the North American sales from the third quarter of 2009. There were strong sales in trauma, attributed to launching new product lines and the continued success of the Matrix facial plating system. The sales of spine products were weaker in the United States, reflecting external challenges and product launch delays.
European sales decreased from $198.6 million during the third quarter of 2009 to $196.5 million during the third quarter of 2010. While Synthes performed well in the trauma market with products such as the Variable Angle LCP and the MatrixMIDFACE, the company struggled with the launch of "Matrix Spine" and targeted competitive conversion initiatives.
Read the release on Synthes 3Q FY 2010 report.
Read other coverage on Synthes:
- Court Issued Mixed Ruling in Medtronic's Appeal of Synthes Patent Dispute
- Synthes Announces 9% Sales Growth in 2009
- Synthes Recalling its Synex II Central Body Spinal Implant